{
    "eid": "2-s2.0-85066117677",
    "title": "Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients",
    "cover-date": "2019-05-24",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Genetics",
            "@code": "1311",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "atazanavir",
        "CYP3A5 6986A>G",
        "plasma concentrations",
        "polymorphisms",
        "ritonavir",
        "SLCO1B1 521T>C"
    ],
    "authors": [
        "Noppaket Singkham",
        "Anchalee Avihingsanon",
        "Narukjaporn Thammajaruk",
        "Kiat Ruxrungtham",
        "Torsak Bunupuradah",
        "Sasisopin Kiertiburanakul",
        "Ploenchan Chetchotisakd",
        "David M. Burger",
        "Sean Emery",
        "Baralee Punyawudho"
    ],
    "citedby-count": 3,
    "ref-count": 57,
    "ref-list": [
        "Atazanavir: A review of its use in the management of HIV-1 infection",
        "Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir",
        "Atazanavir Ctrough is associated with efficacy and safety: Definition of therapeutic range",
        "Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations",
        "Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice",
        "Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naive",
        "Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice",
        "Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring",
        "Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients",
        "Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients",
        "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202",
        "A population pharmacokinetic-pharmacogenetic analysis of atazanavir",
        "Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients",
        "Factors influencing lopinavir and atazanavir plasma concentration",
        "Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients",
        "Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients",
        "The pharmacogenetics of HIV treatment: A practical clinical approach",
        "Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs",
        "Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: A randomized, controlled, pilot study (the REYAGEN study)",
        "Personalizing antiretroviral therapy: Is it a reality?",
        "Individualization of antiretroviral therapy",
        "A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults",
        "Frequency of functional drug disposition gene polymorphism in Thai population: Relevance to antiretroviral drugs",
        "Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia",
        "PharmGKB summary: Very important pharmacogene information for CYP3A5",
        "Genetic contribution to variable human CYP3A-mediated metabolism",
        "Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors",
        "Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients",
        "Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: Update of the literature",
        "Role and modulation of drug transporters in HIV-1 therapy",
        "Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C->T polymorphism at the multidrug resistance gene 1",
        "Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia",
        "Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms",
        "Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1\u2217 28 allele frequency",
        "Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors",
        "CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children",
        "Discordant associations between SLCO1B1 521T->C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146",
        "The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men",
        "HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms",
        "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: A sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)",
        "Nuclear receptor PXR, transcriptional circuits and metabolic relevance",
        "Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C\u2192T) with reduced concentrations of unboosted atazanavir",
        "Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance",
        "Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): A randomised, open-label, non-inferiority trial",
        "The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A global proficiency testing program",
        "Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients",
        "Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART",
        "CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects",
        "Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake",
        "Impact of genetic variation in OATP transporters to drug disposition and response",
        "Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults",
        "Bilirubin - A potential marker of drug exposure in atazanavir-based antiretroviral therapy",
        "In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia",
        "Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation",
        "Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations"
    ],
    "affiliation": [
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Sydney",
            "@id": "60028333",
            "affilname": "UNSW Sydney",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028333",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nijmegen",
            "@id": "60002573",
            "affilname": "Radboud University Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002573",
            "affiliation-country": "Netherlands"
        }
    ],
    "funding": [
        "Janssen/Tibotec",
        "BMS",
        "Merck",
        "Chiang Mai University",
        "Chulalongkorn University",
        "Thailand Research Fund"
    ]
}